NCT00051597View on ClinicalTrials.gov

A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

Not specified

Study Completion Date

August 31, 2003

Conditions

Hodgkin DiseaseLymphoma, Large-CellSarcoma, KaposiLymphoma, T-Cell, CutaneousLymphoma, B-Cell

Interventions

DRUG

SGN-30 (monoclonal antibody)

Trial Locations (10)

10021

Cornell Medical College, New York Presbyterian, New York

14642

University of Rochester, Rochester

33136

University of Miami, Miami

35294

University of Alabama, Birmingham, Birmingham

63110

Siteman Cancer Center, St Louis

68198

University of Nebraska, Omaha

77030

MD Anderson Cancer Center, Houston

90033

USC Norris Cancer Center, Los Angeles

98109

University of Washington, Seattle

02115

Dana Farber Cancer Institute, Boston

All Listed Sponsors

lead

Seagen Inc.

INDUSTRY

NCT00051597 - A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies | Biotech Hunter | Biotech Hunter